COG AHOD1822 / Merck MK-3475-667: An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
Details
Age
Child to Adult
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Lisa Hartman, MD
Study ID
Protocol Number: 19-1481
More information available at ClinicalTrials.gov: NCT03407144
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers